Effective January 1, 2017, new precertification requirements will apply to our commercial HMO and PPO members for the medical benefit drugs listed below:

• Cinqair^® (reslizumab)
• Cubicin^® (daptomycin)
• Darzalex? (daratumumab)
• Erwinaze^® (L-asparaginase)
• Exondys 51^™ (eteplirsen)
• Faslodex^® (fulvestrant)
• Hymovis^® (high molecular weight viscoelastic hyaluronan)
• Inflectra^™ (infliximab)*
• Neulasta^® (pegfilgrastim)*
• Neulasta^® (pegfilgrastim) Onpro^®*
• Sandostatin^® LAR (octreotide acetate)
• Tecentriq^™ (atezolizumab)

In addition, the following drugs are currently pending approval from the U.S. Food and Drug Administration (FDA). Once they receive FDA approval, they will also require precertification approval from AmeriHealth:

• Cingal^® (sodium hyaluronate/triamcinolone hexacetonide)
• Ocrevus^™ (ocrelizumab)
• Remune^® (HIV-1 immunogen)

These changes will be reflected in an updated precertification requirement list, which will be posted to our websites for AmeriHealth New Jersey and for AmeriHealth Pennsylvania in December, prior to these changes going into effect. Look for more information about the availability of this new precertification requirement list in the December 2016 edition of Partners in Health Update^SM.

*Precertification requirements apply to all biosimilars of infliximab and pegfilgratism approved by the FDA.